250 related articles for article (PubMed ID: 16995817)
1. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast.
Baldock PA; Thomas GP; Hodge JM; Baker SU; Dressel U; O'Loughlin PD; Nicholson GC; Briffa KH; Eisman JA; Gardiner EM
J Bone Miner Res; 2006 Oct; 21(10):1618-26. PubMed ID: 16995817
[TBL] [Abstract][Full Text] [Related]
2. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
4. Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio.
Rucci N; Rufo A; Alamanou M; Teti A
J Cell Biochem; 2007 Feb; 100(2):464-73. PubMed ID: 16927271
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
6. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells.
Coetzee M; Haag M; Kruger MC
J Nutr Biochem; 2007 Jan; 18(1):54-63. PubMed ID: 16650751
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.
Hofbauer LC; Dunstan CR; Spelsberg TC; Riggs BL; Khosla S
Biochem Biophys Res Commun; 1998 Sep; 250(3):776-81. PubMed ID: 9784422
[TBL] [Abstract][Full Text] [Related]
8. Alteration of bone cell function by RANKL and OPG in different in vitro models.
Lin JM; Callon KE; Lin CQ; Bava U; Zheng MH; Reid IR; Cornish J
Eur J Clin Invest; 2007 May; 37(5):407-15. PubMed ID: 17461987
[TBL] [Abstract][Full Text] [Related]
9. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival.
Ochi H; Hara Y; Tagawa M; Shinomiya K; Asou Y
J Orthop Res; 2010 May; 28(5):657-63. PubMed ID: 19890995
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
12. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
13. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
14. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
15. Expression of RANKL/OPG during bone remodeling in vivo.
Tanaka H; Mine T; Ogasa H; Taguchi T; Liang CT
Biochem Biophys Res Commun; 2011 Aug; 411(4):690-4. PubMed ID: 21771583
[TBL] [Abstract][Full Text] [Related]
16. Mechanical force inhibits osteoclastogenic potential of human periodontal ligament fibroblasts through OPG production and ERK-mediated signaling.
Kook SH; Son YO; Hwang JM; Kim EM; Lee CB; Jeon YM; Kim JG; Lee JC
J Cell Biochem; 2009 Apr; 106(6):1010-9. PubMed ID: 19206164
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D and bone.
Suda T; Ueno Y; Fujii K; Shinki T
J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
[TBL] [Abstract][Full Text] [Related]
18. RANKL expression is related to the differentiation state of human osteoblasts.
Atkins GJ; Kostakis P; Pan B; Farrugia A; Gronthos S; Evdokiou A; Harrison K; Findlay DM; Zannettino AC
J Bone Miner Res; 2003 Jun; 18(6):1088-98. PubMed ID: 12817763
[TBL] [Abstract][Full Text] [Related]
19. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells.
Poulsen RC; Wolber FM; Moughan PJ; Kruger MC
Prostaglandins Other Lipid Mediat; 2008 Feb; 85(1-2):42-8. PubMed ID: 18077200
[TBL] [Abstract][Full Text] [Related]
20. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]